Original Research
Published on 15 Jan 2025
Parishin B blocking TRIB3-AKT1 interaction inhibits breast cancer lung metastasis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1517708
Type at least 3 characters
2,656 articles
Articles
Case Report
Published on 15 Jan 2025
Case report: Tocilizumab for hypersensitivity reaction after oxaliplatin in a patient with NK/T-cell lymphoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1471038
Original Research
Published on 15 Jan 2025
Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1510851
- 119 views
Original Research
Published on 15 Jan 2025
Oxyresveratrol as a novel ferroptosis inducer exhibits anticancer activity against breast cancer via the EGFR/PI3K/AKT/GPX4 signalling axis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1527286
Review
Accepted on 27 Dec 2024
The mechanism underlying metastasis in triple-negative breast cancer: focusing on the interplay between ferroptosis, epithelial-mesenchymal transition, and non-coding RNAs
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1437022
- 260 views
Review
Accepted on 14 Jan 2025
Side-Stepping the Guardian of the Genome: Current Cancer Therapeutics Targeting Mutant p53
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1529483
Original Research
Published on 14 Jan 2025
DNA methylation inhibitors adverse reaction characteristic analysis: an analysis based on the European spontaneous adverse event reporting system
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1527903
- 100 views
Review
Published on 14 Jan 2025
Hydroxysafflor yellow A: a natural pigment with potential anticancer therapeutic effect
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1495393
Original Research
Accepted on 13 Jan 2025
Exploring Immune-Related Adverse Events: Real-World Insights from 2523 PD-1/PD-L1 Inhibitor Patients
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1519082
Review
Accepted on 13 Jan 2025
Gelatin-based biomaterials as a delivery strategy for osteosarcoma treatment
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1537695
Original Research
Published on 13 Jan 2025
Integration of histone modification-based risk signature with drug sensitivity analysis reveals novel therapeutic strategies for lower-grade glioma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1523779
- 136 views
Original Research
Published on 13 Jan 2025
CSNK1E is involved in TGF-β1 induced epithelial mesenchymal transformationas and related to melanoma immune heterogeneity
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1501849
- 129 views
Systematic Review
Accepted on 10 Jan 2025
Impact of Finasteride on Modulating the Risk and Clinical Outcomes of Bladder Cancer: Insights from a Comprehensive Meta-Analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1471442
Original Research
Accepted on 10 Jan 2025
Exploring the Anti-Metastatic Potential of Sunitinib and Novel Analogs in Colorectal Cancer: Insights into HIF-1α Mediated Metastasis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1520881
Review
Published on 10 Jan 2025
Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1493188
- 261 views
Systematic Review
Accepted on 09 Jan 2025
Comparative Safety Profile of Tyrosine Kinase Inhibitors in NSCLC: A Network Meta-Analysis of Hypertension and Thrombotic Risks
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1491990